CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

uracil

Small moleculeexperimental

Uracil is one of the four nucleotide bases in the nucleic acid RNA. The others are adenine (A), cytosine (C), and guanine (G). In RNA, uracil binds to adenine via two hydrogen bonds. In DNA, the uracil nucleobase is replaced by thymine (T). Uracil is a demethylated form of thymine. — Wikipedia

Clinical trial activity

42 trials · 53 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
35
Phase 3
17
Phase 4
1

Earliest trial started Apr 1, 1996 (NCT00002801)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1996

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetSupplementation

    supplementation

Chemistry & pharmacology

Loading structure…

SMILES

O=c1cc[nH]c(=O)[nH]1
Mol. weight
112.09 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bms-205603-01
  • bms-205603-01
  • sq-6201
  • sq-6201
  • sq-7726
  • sq-7726
  • sq-8493
  • sq-8493
  • uracil
  • uracil
  • uracil
  • uracil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02836977N/AMar 1, 2016Kaohsiung Medical University
NCT02887365Phase 4Sep 1, 2014National Taiwan University
NCT01720563Phase 2Dec 1, 2012Chang Gung University, PhytoHealth Corporation
NCT01539018Phase 2Jan 1, 2012Ain Shams University, Cairo University, Egyptian Society of Liver Cancer, Monofeiya university
NCT02447679Phase 2Aug 1, 2010Chang Gung University
NCT01074710Phase 1Feb 1, 2010Covance, Otsuka
NCT01082510Phase 3Jan 1, 2010Urological Oncology Council of Northern Tokyo
NCT01100463Phase 1/Phase 2 (Phase 2)Dec 1, 2009Birmingham Hematology/Oncology Associates, Cahaba Pharmaceuticals
NCT02903498Phase 2Aug 1, 2009Fudan University
NCT01225744Phase 2Apr 1, 2009Merck, The Christie NHS Foundation Trust
NCT00890188Phase 2Jan 1, 2009National Cheng Kung University
NCT00855881Phase 2Dec 1, 2008Mackay Medical College
NCT00660894Phase 3Apr 1, 2008Tokyo Medical and Dental University, Translational Research Informatics Center, Kobe, Hyogo, Japan
NCT00625352Phase 2Feb 1, 2008Jeil Pharmaceutical Co., Ltd., University of Ulsan
NCT00497107Phase 3Jul 1, 2007Iwate Medical University
NCT00464919Phase 2Apr 1, 2007National Taiwan University
NCT00439517Phase 2Feb 1, 2007Institut de Cancerologie de l'Ouest Paul Papin, Merck KGaA
NCT00392899Phase 3Oct 1, 2006Tokyo Medical and Dental University, Translational Research Informatics Center, Kobe, Hyogo, Japan
NCT00384800Phase 2Sep 1, 2006Far Eastern Memorial Hospital
NCT00519688Phase 2Jul 1, 2006National Taiwan University
Showing 20 of 42 trials
Page 1 / 3

Organizations

Research & Development (53)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government6031997
OtsukaFor profit5521996
National Taiwan UniversityAcademic/Hospital4422003
Chang Gung UniversityAcademic/Hospital2112010
Institut de Cancerologie de l'Ouest Paul PapinAcademic/Hospital2122004
Mackay Medical CollegeAcademic/Hospital2112003
MerckFor profit2022004
National Cheng Kung UniversityAcademic/Hospital2112003
Taipei Veteran General hospitalGovernment2112003
Tokyo Medical and Dental UniversityAcademic/Hospital2012006
Translational Research Informatics Center, Kobe, Hyogo, JapanAcademic/Hospital2212006
University of PittsburghAcademic/Hospital2211999
Ain Shams UniversityAcademic/Hospital1012012
Allegheny Health NetworkAcademic/Hospital1011997
Birmingham Hematology/Oncology AssociatesAcademic/Hospital1012009
Bristol-Myers SquibbFor profit1012002
Cahaba PharmaceuticalsFor profit1112009
Cairo UniversityAcademic/Hospital1012012
Centre des Hautes Energie, ToulouseAcademic/Hospital1012004
Chest Department, Taipei VGHAcademic/Hospital1012005
53 organizations
Page 1 / 3